419 - WHERE CARDIO AND NEPHRO MEET: EXAMINING UACR AS A CV RISK FACTOR

Thursday, October 27, 2022

5:30 PM – 5:50 PM EDT

Location: Canada Hall 2 West

Sponsored By

Target Audience: Clinical cardiologists, Community cardiologists

Presenter(s)

Anil Gupta

Cardiologist
Trillium Health Partners
Mississauga, Ontario, Canada
David M. Weinstein

Staff Nephrologist
Quinte Health
Belleville, Ontario, Canada

Learning Objectives:

At the conclusion of this session, participants will be able to:

evaluate CVD risk in patients with CKD and T2D;
examine the predictive value of UACR for CV risk assessment; and
assess HF hospitalizations outcomes from FIDELIO-DKD and FIGARO-CKD, in patients with renal disease and type 2 diabetes.

Patients with chronic kidney disease and type 2 diabetes are an understudied patient population at high risk of cardiovascular morbidity and mortality. New treatment options are needed in this common patient population to reduce their risk of cardiovascular events. In this Q&A session between a nephrologist and cardiologist, Dr. David Weinstein and Dr. Anil Gupta will discuss the prognostic value of urinary albumin excretion (UACR) for cardiovascular risk assessment in patients with diabetes and CKD, the CV outcomes data FIDELIO-DKD and FIGARO-CKD, and considerations when initiating new treatments in patients with CKD and T2D. Join us for an engaging conversation at CCC 2022.